Meta's AI Capex Panic Misses the Quiet Health-Tech Revolution on Quest This week

Meta's AI Capex Panic Misses the Quiet Health-Tech Revolution on Quest This week, Meta's stock slid after Mark Zuckerberg signaled massive AI infrastructure spend and a pivot to selling AI tools to enterprises. The market reacted to capex. But for a specific slice of developers — and the patients they serve — the real story is what the Quest platform just enabled. AmblyoPunch, a new VR title from Seven Sportz, is the first commercially available dichoptic game designed explicitly for amblyopia (lazy eye) rehabilitation. It uses Gabor-pattern stimuli across a four-stage protocol: players punch coins visible only to the weaker eye while dodging spikes that require binocular fusion. No patches. No tears. Just engagement-driven compliance on a $299 headset. The bridge is unavoidable: the same Quest hardware roadmap subsidized by Meta's AI ambitions is now hosting FDA-exempt, clinically grounded digital therapeutics. For digital health founders, that's the platform signal worth tracking — not the quarterly capex指引